| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 74,081 | 129,126 | ||
| Short-term investment securities | 57,501 | 122,744 | ||
| Accounts receivable, net | 265,384 | 231,516 | ||
| Inventories | 146,953 | 155,202 | ||
| Other current assets | 55,846 | 25,374 | ||
| Total current assets | 599,765 | 663,962 | ||
| Restricted cash | 1,329 | 1,316 | ||
| Long-term investment securities | 48,757 | 28,590 | ||
| Right of use assets | 6,501 | 6,718 | ||
| Deferred tax assets | 366,627 | - | ||
| Other noncurrent assets | 2,045 | 2,027 | ||
| Total assets | 1,025,024 | 702,613 | ||
| Accounts payable and accrued expenses | 112,336 | 134,021 | ||
| Other current liabilities | 1,993 | 2,256 | ||
| Lease liability current portion | 1,068 | 1,091 | ||
| Deferred revenue - current portion | 26,399 | 23,911 | ||
| Accrued compensation | 15,014 | 10,610 | ||
| Total current liabilities | 156,810 | 171,889 | ||
| Deferred revenue, non-current portion | 8,348 | 1,667 | ||
| Loan payable non-current | 245,340 | 245,037 | ||
| Lease liability non-current | 7,308 | 7,588 | ||
| Total liabilities | 417,806 | 426,181 | ||
| Common stock, 0.001 par value per share (190,000,000 and 175,000,000 shares authorized, 158,754,176 and 156,204,159 shares issued, 155,210,533 and 155,836,256 shares outstanding at september 30, 2025 and december 31, 2024, respectively) | 159 | 159 | ||
| Additional paid-in capital | 1,812,345 | 1,794,212 | ||
| Treasury stock, at cost, 761,098 and 367,903 shares at june 30, 2025 and december 31, 2024, respectively | - | 21,992 | ||
| Treasury stock, at cost, 3,543,643 and 367,903 shares at september 30, 2025 and december 31, 2024, respectively | 100,234 | - | ||
| Accumulated deficit | -1,105,052 | -1,495,947 | ||
| Total stockholders equity | 607,218 | 276,432 | ||
| Total liabilities and stockholders equity | 1,025,024 | 702,613 | ||
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)